Clinical Applications of Radio-Frequency Ablation in Liver Metastasis of Colorectal Cancer.
10.3393/jksc.2011.27.4.202
- Author:
Ji Hun GWAK
1
;
Bo Young OH
;
Ryung Ah LEE
;
Soon Sup CHUNG
;
Kwang Ho KIM
Author Information
1. Department of Surgery, Ewha Womans University School of Medicine, Seoul, Korea. eastgate@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Radiofrequency ablation;
Colorectal liver matastasis;
Survival;
Prognostic factor
- MeSH:
Carcinoembryonic Antigen;
Colorectal Neoplasms;
Disease-Free Survival;
Female;
Humans;
Liver;
Male;
Multivariate Analysis;
Neoplasm Metastasis;
Retrospective Studies;
Survival Rate
- From:Journal of the Korean Society of Coloproctology
2011;27(4):202-210
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study is to evaluate long-term survival and prognostic factors for radio-frequency ablation (RFA) in colorectal liver metastases. METHODS: We retrospectively reviewed 35 colorectal liver metastases patients who underwent RFA between 2004 and 2008. We analyzed survival after RFA and prognostic factors for survival. RESULTS: Of the 35 patients, 23 patients were male and 12 were female. Their mean age was 62.40 +/- 12.52 years. Mean overall survival was 38.8 +/- 4.6 months, and mean progression free survival was 19.9 +/- 3.4 months. Three- and 5-year overall survival rates were 42.7 +/- 0.1% and 26.0 +/- 0.1%, respectively. Three- and 5-year progression-free survival rates were 19.6 +/- 0.1% and 4.9 +/- 0.04%, respectively. Overall survival and progression-free survival were significantly improved in male and in patients with carcinoembryonic antigen (CEA) < or = 100 ng/mL, carbohydrate antigen (CA) 19-9 < or = 100 ng/mL, absence of extrahepatic disease, and a unilobar hepatic lesion. In addition, progression-free survival was improved in patients with a solitary hepatic lesion. On the multivariate analysis, significant survival factors were the absence of extrahepatic disease and the presence of a unilobar hepatic lesion. CONCLUSION: RFA for colorectal liver metastases is an effective treatment option in male patients and in patients with CEA or CA19-9 < or = 100, absence of extrahepatic disease, a solitary hepatic lesion, and a unilobar hepatic lesion.
